Biotie Therapies - Company Announcement

FINAL RESULTS OF ACORDA'S TENDER OFFER AND COMMENCEMENT OF A SUBSEQUENT OFFER PERIOD

BIOTIE THERAPIES CORP.         STOCK  EXCHANGE  RELEASE    13 April 2016, at
5.10 p.m  (EET)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION
IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW.

FINAL RESULTS OF ACORDA THERAPEUTICS' VOLUNTARY TENDER OFFER FOR ALL OF THE
ISSUED AND OUTSTANDING SHARES, AMERICAN DEPOSITARY SHARES, STOCK OPTIONS, SHARE
UNITS AND WARRANTS IN BIOTIE THERAPIES CORP. AND COMMENCEMENT OF A SUBSEQUENT
OFFER PERIOD

As previously announced, on 11 March 2016, Acorda Therapeutics, Inc. (Nasdaq:
ACOR) ("Acorda" or the "Offeror") commenced a voluntary public tender offer to
purchase all of the issued and outstanding shares ("Shares"), American
Depositary Shares ("ADSs"), stock options ("Option Rights"), share units ("Share
Rights") and warrants ("Warrants") (such securities, collectively, the "Equity
Interests") in Biotie Therapies Corp (Nasdaq Helsinki: BTH1V; Nasdaq: BITI)
("Biotie" or the "Company") that are not owned by Biotie or any of its
subsidiaries (the "Tender Offer").  The Tender Offer expired on 8 April 2016.

Biotie has today been informed by Acorda that Acorda announced the final results
of the Tender Offer. 656,484,443 Shares, 3,120,541 ADSs, 435,000 2011 Option
Rights, 4,280,125 2014 Option Rights, 12,401,120 2016 Option Rights, 1,949,116
Swiss Option Rights, 25,000 2011 Share Rights, 3,972,188 2014 Share Rights and
220,400,001 Warrants were tendered in the Tender Offer by the expiration date,
representing approximately 93.77 percent of all the shares and votes in Biotie
on a fully-diluted basis as defined in the terms and conditions of the Tender
Offer.

The Shares and ADSs tendered in the Tender Offer represent approximately 92.38
percent of all the shares and votes in Biotie (excluding treasury shares held by
Biotie) and by exercising the other tendered Equity Interests for the
subscription of Biotie shares, the Offeror could increase its holding to
approximately 93.91 percent of all the shares and votes in Biotie (excluding
treasury shares held by Biotie).

As announced on 11 April 2016, all the conditions to completion of the Tender
Offer have been satisfied and the Offeror will complete the Tender Offer in
accordance with its terms and conditions. The offer consideration will be paid
to the holders of Equity Interests who validly accepted the Tender Offer by 8
April 2016 in accordance with the terms and conditions of the Tender Offer on or
about 18 April 2016.

In order to allow holders of Equity Interests who had not tendered their Equity
Interests by 8 April 2016 to accept the Tender Offer, the Offeror has today
decided to commence a subsequent offer period in accordance with the terms and
conditions of the Tender Offer (the "Subsequent Offer Period"). The Subsequent
Offer Period will commence at 9:30 a.m. (EET) / 2:30 a.m. (New York Time) on 14
April 2016 and expire at 4:00 p.m. (EET) / 9:00 a.m. (New York Time) on 28 April
2016.

During the Subsequent Offer Period, the Tender Offer can be accepted in
accordance with the acceptance procedures described in the terms and conditions
of the Tender Offer. The acceptance of the Tender Offer during the Subsequent
Offer Period is binding and cannot be withdrawn. Further information and
instructions can be obtained from any branch office of the cooperative banks
belonging to the OP Financial Group or Helsinki OP Bank Ltd.

Payment for and acceptance of Equity Interests validly tendered during the
Subsequent Offer Period will take place on a periodic basis in intervals of one
(1) week. The first acceptance date will be 21 April 2016 and the offer
consideration for Equity Interests validly tendered during the Subsequent Offer
period on or before the first acceptance date will be made on or about 27 April
2016. The second acceptance date will be 28 April 2016 and the offer
consideration for Equity Interests validly tendered during the Subsequent Offer
period on or before the second acceptance date will be made on or about 4 May
2016.

The Offeror will announce the final percentage of the Equity Interests validly
tendered during the Subsequent Offer Period on or about 2 May 2016.

Acorda's press release is enclosed to this stock exchange release as an
attachment.


Turku, 13 April 2016

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

INFORMATION REGARDING BIOTIE

Biotie is a biopharmaceutical company focused on products for neurodegenerative
and psychiatric disorders. Biotie's development has delivered Selincro
(nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being marketed across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is in Phase 3 development, and two additional compounds which are
in Phase 2 development for cognitive disorders including Parkinson's disease
dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of
the liver.

INFORMATION REGARDING ACORDA

Founded in 1995, Acorda is a biotechnology company focused on developing
therapies that improve the lives of people with neurological disorders, with its
common stock listed on Nasdaq US.

Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including multiple sclerosis, Parkinson's
disease, post-stroke walking deficits, epilepsy and migraine. Acorda markets
three FDA-approved therapies, including AMPYRA (dalfampridine) Extended Release
Tablets, 10 mg.

ADDITIONAL INFORMATION

Investors  and holders of Biotie equity  securities are strongly advised to read
the  tender  offer  statement,  including  the  offer  to  purchase,  letter  of
transmittal,  acceptance forms and other related  tender offer documents and the
related  solicitation/recommendation statement on Schedule 14D-9 filed by Biotie
with  the United States Securities and  Exchange Commission (the "SEC"), because
they  contain important information. These documents  are available at no charge
on  the SEC's website  at www.sec.gov. In  addition, a copy  of the Tender Offer
Document  and related documents may be obtained free of charge at www.acorda.com
or Office of the Corporate Secretary, 420 Saw Mill River Road, Ardsley, New York
10502.

In  addition  to  the  Schedule  TO,  Acorda files annual, quarterly and special
reports,  proxy statements and other information with  the SEC. You may read and
copy  any reports, statements  or other information  filed by Acorda  at the SEC
public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call
the  SEC at 1-800-SEC-0330 for further information on the public reference room.
Acorda's  filings with the SEC are also  available to the public from commercial
document-retrieval  services  and  at  the  website  maintained  by  the  SEC at
www.sec.gov.

THE  TENDER OFFER  IS NOT  AND WILL  NOT BE  MADE DIRECTLY  OR INDIRECTLY IN ANY
JURISDICTION  WHERE EITHER  AN OFFER  OR PARTICIPATION  THEREIN IS PROHIBITED BY
APPLICABLE  LAW  OR  WHERE  ANY  TENDER  OFFER DOCUMENT OR REGISTRATION OR OTHER
REQUIREMENTS  WOULD APPLY  IN ADDITION  TO THOSE  UNDERTAKEN IN  FINLAND AND THE
UNITED STATES.

IN  ADDITION, THE TENDER OFFER DOCUMENT,  THE RELATED DOCUMENTS AND THIS RELEASE
WILL  NOT AND MAY NOT BE DISTRIBUTED,  FORWARDED OR TRANSMITTED INTO OR FROM ANY
JURISDICTION WHERE PROHIBITED BY APPLICABLE LAW. IN PARTICULAR, THE TENDER OFFER
IS NOT BEING MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, CANADA, JAPAN, AUSTRALIA,
SOUTH  AFRICA OR HONG KONG. THE TENDER OFFER CANNOT BE ACCEPTED BY ANY SUCH USE,
MEANS  OR INSTRUMENTALITY OR FROM WITHIN  CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA
OR HONG KONG.

This release is for informational purposes only and does not constitute a tender
offer document or an offer, solicitation of an offer or an invitation to a sales
offer.  Potential investors in Finland shall accept the Tender Offer only on the
basis  of the information provided in the  Tender Offer Document approved by the
Finnish Financial Supervisory Authority and related materials.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this announcement are forward-looking
statements, including statements regarding the expected consummation of the
acquisition, which involves a number of risks and uncertainties, including the
satisfaction of closing conditions for the acquisition, such as the possibility
that the transaction will not be completed and other risks and uncertainties
discussed in the Tender Offer documents filed by Acorda and the
solicitation/recommendation statement filed by the Company. These statements are
based on current expectations, assumptions, estimates and projections, and
involve known and unknown risks, uncertainties and other factors that may cause
results, levels of activity, performance or achievements to be materially
different from any future statements. These statements are generally identified
by words or phrases such as "believe", "anticipate", "expect", "intend", "plan",
"will", "may", "should", "estimate", "predict", "potential", "continue" or the
negative of such terms or other similar expressions. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual results
and the timing of events may differ materially from the expected results and/or
timing discussed in the forward-looking statements, and you should not place
undue reliance on these statements. Acorda and the Company disclaim any intent
or obligation to update any forward-looking statements as a result of
developments occurring after the period covered by this announcement or
otherwise.


[HUG#2003262]

Attachments:

Acorda´s press release.pdf